blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3041503

EP3041503 - METHODS AND COMPOSITIONS FOR VIRAL VECTORED VACCINES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  02.10.2020
Database last updated on 03.10.2024
FormerExamination is in progress
Status updated on  13.11.2019
Most recent event   Tooltip02.10.2020Application deemed to be withdrawnpublished on 04.11.2020  [2020/45]
Applicant(s)For all designated states
Altimmune Inc.
19 Firstfield Road, Ste 200
Gaithersburg, MD 20878 / US
[2016/28]
Inventor(s)01 / TANG, De-chu
1163 Riverchase Parkway West
Birmingham, AL 35244 / US
 [2016/28]
Representative(s)Bates, Rosica Florence
Brunswick IP Limited
6 Brunswick Cottages
Midsummer Common
Cambridge CB5 8DL / GB
[2016/28]
Application number, filing date14841665.405.09.2014
[2016/28]
WO2014US54234
Priority number, dateUS201361874505P06.09.2013         Original published format: US 201361874505 P
[2016/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015035128
Date:12.03.2015
Language:EN
[2015/10]
Type: A1 Application with search report 
No.:EP3041503
Date:13.07.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 12.03.2015 takes the place of the publication of the European patent application.
[2016/28]
Search report(s)International search report - published on:US12.03.2015
(Supplementary) European search report - dispatched on:EP11.05.2017
ClassificationIPC:A61K39/12, A61K39/23, A61K45/00, A61K39/00
[2017/23]
CPC:
A61K39/12 (EP,KR,US); A61K39/235 (KR); A61P37/04 (EP);
A61K2039/5256 (EP,KR,US); A61K2039/545 (EP,KR,US); A61K2039/55561 (EP,KR,US);
C12N2710/10343 (EP,KR,US); C12N2760/16134 (EP,KR,US) (-)
Former IPC [2016/28]A61K39/12, A61K39/23, A61K45/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/28]
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN FÜR VIRALE VEKTORISIERTE IMPFSTOFFE[2016/28]
English:METHODS AND COMPOSITIONS FOR VIRAL VECTORED VACCINES[2016/28]
French:MÉTHODES ET COMPOSITIONS POUR VACCINS VIRAUX VECTORISÉS[2016/28]
Entry into regional phase06.04.2016National basic fee paid 
06.04.2016Search fee paid 
06.04.2016Designation fee(s) paid 
06.04.2016Examination fee paid 
Examination procedure06.04.2016Examination requested  [2016/28]
11.12.2017Amendment by applicant (claims and/or description)
18.11.2019Despatch of a communication from the examining division (Time limit: M06)
03.06.2020Application deemed to be withdrawn, date of legal effect  [2020/45]
26.06.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2020/45]
Fees paidRenewal fee
27.09.2016Renewal fee patent year 03
27.09.2017Renewal fee patent year 04
27.09.2018Renewal fee patent year 05
27.09.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XYI]WO2012129295  (VAXIN INC [US], et al) [X] 1-4,7-11,13,14 * claims 1-15 * [Y] 5,6,15 [I] 12;
 [XYI]  - C. D. SCALLAN ET AL, "An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models", CLINICAL AND VACCINE IMMUNOLOGY, US, (20121114), vol. 20, no. 1, doi:10.1128/CVI.00552-12, ISSN 1556-6811, pages 85 - 94, XP055361762 [X] 1-4,7-11,13,14 * the whole document * [Y] 5,6,15 [I] 12

DOI:   http://dx.doi.org/10.1128/CVI.00552-12
 [Y]  - Hideki Hasegawa ET AL, "Development of mucosal adjuvants for intranasal vaccine for H5N1 infl uenza viruses", Therapeutics and Clinical Risk Management, (20090101), pages 5 - 125, URL: https://pdfs.semanticscholar.org/3b65/a4aa5c6b9c0e67500d4d92d3e1d6e892c916.pdf, XP055361759 [Y] 5,6,15 * page 127, column lhc, paragraph 2 *
 [Y]  - D. R. BRAUCHER ET AL, "Intranasal Vaccination with Replication-Defective Adenovirus Type 5 Encoding Influenza Virus Hemagglutinin Elicits Protective Immunity to Homologous Challenge and Partial Protection to Heterologous Challenge in Pigs", CLINICAL AND VACCINE IMMUNOLOGY, (20121101), vol. 19, no. 11, doi:10.1128/CVI.00315-12, ISSN 1556-6811, pages 1722 - 1729, XP055132141 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1128/CVI.00315-12
 [Y]  - KUMAKI Y ET AL, "Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 89, no. 1, ISSN 0166-3542, (20110101), pages 75 - 82, (20110101), XP027586729 [Y] 1-15 * abstract *
 [A]  - M. CASKEY ET AL, "Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans", THE JOURNAL OF IMMUNOLOGY, (20111107), vol. 181, no. 1, doi:10.1371/journal.pone.0009753, ISSN 0022-1767, pages 276 - 2366, XP055110391 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1084/jem.20111171
 [A]  - PETERS WENDY ET AL, "Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-[gamma] T cell responses in humans", VACCINE, ELSEVIER, AMSTERDAM, NL, (20130125), vol. 31, no. 13, doi:10.1016/J.VACCINE.2013.01.023, ISSN 0264-410X, pages 1752 - 1758, XP028998365 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vaccine.2013.01.023
International search[X]US2006223742  (SALAZAR ANDRES M [US]);
 [X]US2011081375  (TUCKER SEAN N [US])
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.